Updated:
Abzena
Abzena was founded more than 20 years ago and has grown into a CDMO+CRO focused exclusively on complex biologics and bioconjugates.
Abzena
Abzena was founded more than 20 years ago and has grown into a CDMO+CRO focused exclusively on complex biologics and bioconjugates. The firm’s wealth origin is not publicly attributed to any family or principal; it operates as a standalone contract research and manufacturing organization. The firm provides integrated services across multiple modalities including monoclonal antibodies, antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), and radiopharmaceutical drug conjugates (RDCs). Its capabilities span antibody discovery, cell line development, immunogenicity testing, formulation, process development, and clinical through commercial cGMP manufacturing. Abzena lists over 1400 lead candidates discovered and over 2000 bioconjugates developed, including 400 ADCs produced (per the firm, 2026). Geographic footprint includes facilities in San Diego, CA; Bristol, PA; and Cambridge, UK. Abzena reports a team of scientific experts across these three locations. The firm has developed proprietary technologies including AbZelectPRO cell line platforms, EpiScreen 2.0 immunogenicity assays, Composite Human Antibody humanization, ThioBridge conjugation linker, and LabZient analytical platform. No recent operational event was publicly verifiable beyond ongoing service offerings. Abzena differentiates by offering fully integrated early R&D through commercial manufacturing under one organization, a structure it claims reduces white space, risk, and timelines compared to fragmented service providers. The firm emphasizes a focus on complex and challenging programs that other CDMOs may avoid.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
United Kingdom
City
Cambridge
Corporate office
Cambridge, United Kingdom
Additional offices
San Diego, CA, USA · Bristol, PA, USA
Sector focus
Frequently asked questions
What services does Abzena offer?
Abzena provides integrated biologics and bioconjugates CDMO+CRO services covering antibody discovery, engineering, developability assessment, analytics, immunogenicity assays, cell line development, formulation, process development, and cGMP manufacturing for clinical through commercial supply.
Where are Abzena's facilities located?
Abzena operates three facilities: San Diego, CA (development and manufacturing), Bristol, PA (discovery and manufacturing), and Cambridge, UK (development and discovery).
What modalities does Abzena work with?
Abzena works with monoclonal antibodies, antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), radiopharmaceutical drug conjugates (RDCs), fusion proteins, bispecifics, and other complex biologics.
Does Abzena have proprietary technologies?
Yes, Abzena has developed several proprietary platforms including AbZelectPRO cell line development, EpiScreen 2.0 immunogenicity testing, Composite Human Antibody humanization, ThioBridge conjugation linker, and LabZient analytical data platform.
Does Abzena only serve large pharma?
No, Abzena serves pharmaceutical and biotech companies of all sizes, with a stated focus on complex and challenging programs that other CDMOs may avoid.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: